IgY在抗病毒医学领域中的应用

doi:10.19586/j.2095-2341.2023.0107

生物技术进展 ›› 2024, Vol. 14 ›› Issue (1): 35-41.DOI: 10.19586/j.2095-2341.2023.0107

• 生物制品研发与技术专题 • 上一篇下一篇

IgY在抗病毒医学领域中的应用

张永红(), 李岩异(), 刘容麟, 吕娜, 张卫婷

华北制药金坦生物技术股份有限公司，石家庄　050035

收稿日期:2023-09-12 接受日期:2023-10-27 出版日期:2024-01-25 发布日期:2024-02-05
通讯作者: 李岩异
作者简介:张永红 E-mail: yhzh9967@163.com；

Application of IgY in the Field Antiviral Medical

Yonghong ZHANG(), Yanyi LI(), Ronglin LIU, Na LYU, Weiting ZHANG

North China Pharmaceutical Jintan Biotechnology Co. ，Ltd. ，Shijiazhuang 050035，China

Received:2023-09-12 Accepted:2023-10-27 Online:2024-01-25 Published:2024-02-05
Contact: Yanyi LI

摘要/Abstract

摘要：

免疫球蛋白Y（immunoglobulin Y, IgY）作为一种潜在的治疗性抗体，存在于许多物种内，从低等的两栖类、爬行类到高等动物鸟类等。疫苗的研发成为全球科学家与病毒“赛跑”的竞争主场。疫苗虽能有效预防病毒的感染，降低疾病的发生率和死亡率，但其开发耗时且成本高昂。IgY具有易生产、成本低、起效快的优点，近年来基于IgY的抗体治疗策略得到广泛认可。概述了IgY特性的最新研究和生产技术的进展，综述了IgY在病毒性疾病治疗方面的应用，从而为IgY在病毒感染性疾病治疗领域的应用提供一些启示。

关键词: IgY, 免疫疗法, 病毒感染性疾病

Abstract:

Immunoglobulin Y （IgY）， as a potential therapeutic antibody， is present in many species， from lower amphibians and reptiles to higher animal birds. The development of vaccines has become a competitive arena for global scientists to compete against viruses. Although the vaccine can effectively prevent the infection of the virus， reduce the incidence and mortality of the disease， but the development of the vaccine is time-consuming and costly. IgY has the advantages of easy production， low cost， take effect quickly， and antibody therapy strategies basedon IgY have been widely recognized in recent years. This review focused on the application of IgY in the treatment of viral diseases by reporting the latest research on the characteristics of IgY and the progress of production technology， so as to provide some enlightenment for the application of IgY in the treatment of viral infectious diseases.

Key words: immunoglobulin Y, immunotherapy, viral infectious disease

中图分类号:

Q511

张永红, 李岩异, 刘容麟, 吕娜, 张卫婷. IgY在抗病毒医学领域中的应用[J]. 生物技术进展, 2024, 14(1): 35-41.

Yonghong ZHANG, Yanyi LI, Ronglin LIU, Na LYU, Weiting ZHANG. Application of IgY in the Field Antiviral Medical[J]. Current Biotechnology, 2024, 14(1): 35-41.

图/表 2

参考文献 47

1	REZAEIFARD M, SOLHI R, MOHAMMADI M, et al.. Production of IgY polyclonal antibody against diphtheria toxin and evaluation of its neutralization effect by Vero cell assay[J/OL]. BMC Biotechnol., 2021, 21(1): 34[2023-11-10]. .
2	LEÓN-NÚÑEZ D, VIZCAÍNO-LÓPEZ M F, ESCORCIA M, et al.. IgY antibodies as biotherapeutics in biomedicine[J/OL]. Antibod. Basel, 2022, 11(4): 62[2023-11-10]. .
3	DIAS DA SILVA W, TAMBOURGI D V. IgY: a promising antibody for use in immunodiagnostic and in immunotherapy[J]. Vet. Immunol. Immunopathol., 2010, 135(3-4): 173-180.
4	LARSSON A, KARLSSON-PARRA A, SJÖQUIST J. Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors[J]. Clin. Chem., 1991, 37(3): 411-414.
5	LEE L, SAMARDZIC K, WALLACH M, et al.. Immunoglobulin Y for potential diagnostic and therapeutic applications in infectious diseases[J/OL]. Front. Immunol., 2021, 12: 696003[2023-11-10]. .
6	SALAZAR G, ZHANG N, FU T M, et al.. Antibody therapies for the prevention and treatment of viral infections[J/OL]. NPJ Vaccines, 2017, 2: 19[2023-11-10]. .
7	ABBAS A T, EL-KAFRAWY S A, SOHRAB S S, et al.. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections[J]. Hum. Vaccin. Immunother., 2019, 15(1): 264-275.
8	林冠峰, 吴英松, 杨懿祺, 等. 抗体药物的发展与应用 [J]. 生物技术进展, 2022, 12(3): 358-365.
	YANG Y, ZHANG Z, YOU X, et al.. Development and application of monoclonal antibody-based erug[J]. Curr. Biotechnol., 2022, 12(3): 358-365.
9	WARR G W, MAGOR K E, HIGGINS D A. IgY: clues to the origins of modern antibodies[J]. Immunol. Today, 1995, 16(8): 392-398.
10	CHALGHOUMI R, BECKERS Y, PORTETELLE D, et al.. Hen egg yolk antibodies (IgY), production and use for passive immunization against bacterial enteric infections in chicken: a review[J]. Biotechnol. Agron. Soc. Environ., 2009, 13(2): 295-308.
11	KOVACS-NOLAN J, MINE Y. Egg yolk antibodies for passive immunity[J]. Annu. Rev. Food Sci. Technol., 2012, 3: 163-182.
12	李岩异,吕娜,贾思凝,等.体外组装的病毒样颗粒在疫苗和药物递送中的应用[J].生物技术进展,2023,13(2):201-209.
	LI Y Y, LYU N, JIA S N, et al.. Application of virus like particles assembled in vitro in vaccine and drug delivery[J]. Curr. Biotechnol., 2023, 13(2): 201-209.
13	彭晓燕,陆盼盼,胡祖权.新型冠状病毒RBD蛋白原核表达及多克隆抗体的制备[J].生物技术进展,2023,13(1):102-106.
	PENG X Y, LU P P, HU Z Q. Prokaryotic expression of the RBD protein of SARS-CoV-2 and its polyclonal antibodies preparation[J]. Curr. Biotechnol., 2023, 13(1): 102-106.
14	SVENDSEN BOLLEN L, CROWLEY A, STODULSKI G, et al.. Antibody production in rabbits and chickens immunized with human IgG. A comparison of titre and avidity development in rabbit serum, chicken serum and egg yolk using three different adjuvants[J]. J. Immunol. Methods, 1996, 191(2): 113-120.
15	LEIVA C L, GALLARDO M J, CASANOVA N, et al.. IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials[J/OL]. Int. Immunopharmacol., 2020, 81: 106269[2023-11-20]..
16	LI X, WANG L, ZHEN Y, et al.. Chicken egg yolk antibodies (IgY) as non-antibiotic production enhancers for use in swine production: a review[J/OL]. J. Anim. Sci. Biotechnol., 2015, 6(1): 40[2023-11-20]. .
17	AHMAD AMRO W, AL-QAISI W, AL-RAZEM F. Production and purification of IgY antibodies from chicken egg yolk[J]. J. Genet. Eng. Biotechnol., 2018, 16(1): 99-103.
18	周水娟,郭忠建.双分子荧光互补技术在动物病毒中的研究进展[J].生物技术进展,2022,12(6):825-836.
	ZHOU S J, GUO Z J. Progress of bimolecular fluorescence complementation technology in animal viruses research[J]. Curr. Biotechnol., 2022, 12(6): 825-836.
19	DEMICHELI V, JEFFERSON T, FERRONI E, et al.. Vaccines for preventing influenza in healthy adults[J/OL]. Cochrane Database Syst. Rev., 2018, 2(2): CD001269[2023-11-20]. .
20	FERGUSON N M, GALVANI A P, BUSH R M. Ecological and immunological determinants of influenza evolution[J]. Nature, 2003, 422(6930): 428-433.
21	NGUYEN H H, TUMPEY T M, JPARK H, et al.. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice[J/OL]. PLoS ONE, 2010, 5(4): e10152[2023-11-20]. .
22	WALLACH M G, WEBBY R J, ISLAM F, et al.. Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice[J]. Clin. Vaccine Immunol., 2011, 18(7): 1083-1090.
23	WEN J, ZHAO S, HE D, et al.. Preparation and characterization of egg yolk immunoglobulin Y specific to influenza B virus[J]. Antiviral Res., 2012, 93(1): 154-159.
24	RAHMAN S, HIGO-MORIGUCHI K, HTUN K W, et al.. Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients[J]. Vaccine, 2012, 30(31): 4661-4669.
25	RAHMAN S, UMEDA K, ICATLO F C, et al.. In vitro cytoprotective effect of infant milk formula fortified with human rotavirus-specific hyperimmune yolk immunoglobulins (IgY)[J]. Food Sci. Biotechnol., 2013, 22(6): 1699-1705.
26	XIE Y M, GAO S, WANG L Y, et al.. Therapeutic effect of probiotics and oral IgY as supplementary drugs in the treatment of pediatric rotavirus enteritis: a comparative study[J]. Chin. J. Contempor. Ped., 2013, 15(11): 1000-1005.
27	WANG X, SONG L, TAN W, et al.. Clinical efficacy of oral immunoglobulin Y in infant rotavirus enteritis: systematic review and meta-analysis[J/OL]. Medicine, 2019, 98(27): e16100[2023-11-20]. .
28	O'DONNELL K L, MEBERG B, SCHILTZ J, et al.. Zika virus-specific IgY results are therapeutic following a lethal zika virus challenge without inducing antibody-dependent enhancement[J/OL]. Viruses, 2019, 11(3): 301[2023-11-20]. .
29	ZHANG Y， WEI Y， LI Y， et al.. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability［J/OL］. PLoS Negl. Trop. Dis.， 2021， 15（3）： e0008403［2023-11-20］. .
30	ABBAS A T, EL-KAFRAWY S A, SOHRAB S S, et al.. Anti-S1 MERS-COV IgY specific antibodies decreases lung inflammation and viral antigen positive cells in the human transgenic mouse model[J/OL]. Vaccines, 2020, 8(4): 634[2023-11-20]. .
31	BROCATO R, JOSLEYN M, BALLANTYNE J, et al.. DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)[J/OL]. PLoS ONE, 2012, 7(4): e35996[2023-11-20]. .
32	FLIOU J, CHANG C W, JTAILIU J, et al.. Passive protection effect of chicken egg yolk immunoglobulins on enterovirus 71 infected mice[J]. Vaccine, 2010, 28(51): 8189-8196.
33	FERELLA A, BELLIDO D, CHACANA P, et al.. Chicken egg yolk antibodies against bovine respiratory syncytial virus neutralize the virus in vitro [J]. Procedia Vaccinol., 2012, 6: 33-38.
34	唐颖,武建强.肉苁蓉苯乙醇苷的抗肿瘤作用[J].生物技术进展,2023,13(3):399-405.
	TANG Y, WU J Q. Anti-tumor effects of phenylethanoid glycosides deprived from Cistanche deserticola [J]. Curr. Biotechnol., 2023, 13(3): 399-405.
35	BAILEY J R, BARNES E, COX A L. Approaches, progress, and challenges to hepatitis C vaccine development[J]. Gastroenterology, 2019, 156(2): 418-430.
36	GUO H, ZHOU E M, SUN Z F, et al.. Immunodominant epitopes mapped by synthetic peptides on the capsid protein of avian hepatitis E virus are non-protective[J]. Viral Immunol., 2008, 21(1): 61-67.
37	OMATA M, UCHIUMI K, ITO Y, et al.. Duck hepatitis B virus and liver diseases[J]. Gastroenterology, 1983, 85(2): 260-267.
38	ABOUZID K, NDEBOKO B, DURANTEL S, et al.. Genetic vaccination for production of DNA-designed antibodies specific to Hepadnavirus envelope proteins[J]. Vaccine, 2006, 24(21): 4615-4617.
39	WIDJAJA I, WANG C, VAN HAPEREN R, et al.. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein[J]. Emerg. Microbes Infect., 2019, 8(1): 516-530.
40	高敏宜, 徐笑, 高已雯, 等. 微量元素硒在对抗COVID-19中的作用研究进展[J]. 生物技术进展, 2023, 13(1): 72-76.
	KAU M, XU X, GAO Y W, et al.. Narrative review on the roles of selenium against COVID-19[J]. Curr. Biotechnol., 2023, 13(1): 72-76.
41	ZUMLA A, HUI D S, PERLMAN S. Middle East respiratory syndrome[J]. Lancet, 2015, 386(9997): 995-1007.
42	SHEAHAN T P, SIMS A C, LEIST S R, et al.. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J/OL]. Nat. Commun., 2020, 11(1): 222[2023-11-20]. .
43	ZAKI S R, GREER P W, COFFIELD L M, et al.. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease[J]. Am. J. Pathol., 1995, 146(3): 552-579.
44	CUSTER D M, THOMPSON E, SCHMALJOHN C S, et al.. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine[J]. J. Virol., 2003, 77(18): 9894-9905.
45	KOMATSU H, SHIMIZU Y, TAKEUCHI Y, et al.. Outbreak of severe neurologic involvement associated with Enterovirus 71 infection[J]. Pediatr. Neurol., 1999, 20(1): 17-23.
46	STOTT E J, TAYLOR G. Respiratory syncytial virus[J]. Arch. Virol., 1985, 84(1): 1-52.
47	VAN DER POEL W H, BRAND A, KRAMPS J A, et al.. Respiratory syncytial virus infections in human beings and in cattle[J]. J. Infect., 1994, 29(2): 215-228.

病原体		给药对象及方式	作用	参考文献
流感病毒	H5N1	小鼠，鼻内给药	抗流感IgY，通过与病毒表位结合，预防小鼠感染H5N1病毒	[21]
	H1N1、H3N2、H5N1	体外实验	IgY抗体具有抑制同源毒株的作用	[22]
	IBV	体外实验	具有抑制血凝素和神经氨酸酶的活性，并抑制病毒的复制	[23]
	IBV	小鼠，鼻内给药	预防乙型流感的发生和减缓疾病的进展	[23]
轮状病毒		轮状病毒患儿，口服	减少了口服补液的用量，缩短了病程	[24]
		体外实验	特异性IgY能够以剂量依赖的方式抑制细胞损伤和轮状病毒粘附	[25]
		轮状病毒患儿，口服	IgY比益生菌能更有效地缩短病程，并显著减少腹泻的频率	[26]
		轮状病毒患儿，口服	抗轮状病毒IgY明显比常规治疗更有效	[27]
寨卡病毒		体外实验	在斑块减少中和实验中，产生的保护作用大于50%	[28]
寨卡病毒		小鼠，腹腔注射	可保护小鼠免受致命的寨卡病毒攻击3周	[28]
埃博拉病毒		小鼠，腹腔注射	高剂量IgY可达到完全的保护作用，而注射低剂量IgY则表现出部分的保护作用	[29]
MERS-CoV		体外实验	特异性的IgY对MERS-CoV具有中和效果	[30]
汉坦病毒		体外实验	具有中和ANDV的能力	[31]
汉坦病毒		小鼠，鼻内给药	可保护仓鼠免受ANDV的攻击	[31]
EV71		小鼠，腹腔注射和口服给药	能显著降低EV71感染幼鼠的发病率和死亡率	[32]
BRSV		体外实验	抗BRSV IgY特异性识别BRSV并能中和该病毒	[33]

病原体		给药对象及方式	作用	参考文献
流感病毒	H5N1	小鼠，鼻内给药	抗流感IgY，通过与病毒表位结合，预防小鼠感染H5N1病毒	[21]
	H1N1、H3N2、H5N1	体外实验	IgY抗体具有抑制同源毒株的作用	[22]
	IBV	体外实验	具有抑制血凝素和神经氨酸酶的活性，并抑制病毒的复制	[23]
	IBV	小鼠，鼻内给药	预防乙型流感的发生和减缓疾病的进展	[23]
轮状病毒		轮状病毒患儿，口服	减少了口服补液的用量，缩短了病程	[24]
		体外实验	特异性IgY能够以剂量依赖的方式抑制细胞损伤和轮状病毒粘附	[25]
		轮状病毒患儿，口服	IgY比益生菌能更有效地缩短病程，并显著减少腹泻的频率	[26]
		轮状病毒患儿，口服	抗轮状病毒IgY明显比常规治疗更有效	[27]
寨卡病毒		体外实验	在斑块减少中和实验中，产生的保护作用大于50%	[28]
寨卡病毒		小鼠，腹腔注射	可保护小鼠免受致命的寨卡病毒攻击3周	[28]
埃博拉病毒		小鼠，腹腔注射	高剂量IgY可达到完全的保护作用，而注射低剂量IgY则表现出部分的保护作用	[29]
MERS-CoV		体外实验	特异性的IgY对MERS-CoV具有中和效果	[30]
汉坦病毒		体外实验	具有中和ANDV的能力	[31]
汉坦病毒		小鼠，鼻内给药	可保护仓鼠免受ANDV的攻击	[31]
EV71		小鼠，腹腔注射和口服给药	能显著降低EV71感染幼鼠的发病率和死亡率	[32]
BRSV		体外实验	抗BRSV IgY特异性识别BRSV并能中和该病毒	[33]

[1]	高朗, 于思雪, 袁春森, 单志伟, 赵鹏翔. 黏蛋白在肿瘤免疫治疗中的研究进展[J]. 生物技术进展, 2023, 13(3): 390-398.
[2]	薛雯,贾宇,江一帆,李辰新,王志明. 免疫检查点抑制剂在肿瘤治疗中的研究进展[J]. 生物技术进展, 2019, 9(4): 341-349.

IgY在抗病毒医学领域中的应用

Application of IgY in the Field Antiviral Medical

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 47

相关文章 2

编辑推荐

Metrics

本文评价